FANCI cooperates with IMPDH2 to promote lung adenocarcinoma tumor growth via a MEK/ERK/ MMPS pathway

16Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: Fanconi anemia complementation group I (FANCI) is a key protein in ribosome biogenesis and DNA repair. Here, we aimed to determine the clinical significance, prognostic value and biology functions of FANCI in lung adenocarcinoma (LUAD). Methods: The expression of FANCI in LUAD tissue and its relationship with patient outcomes were assessed using bioinformatics analysis, as well as quantitative reverse-transcription PCR (qRT-PCR) and Western blot analysis of LUAD tissue and adjacent normal lung tissue. The chi-squared test and Cox regression analysis were used to analyze the clinical significance of FANCI expression. The biological effects of FANCI knockdown in human LUAD cell lines were investigated by analysis of proliferation, colony formation, cell cycle distribution, migration, and invasion in vitro, and monitoring of tumor xenograft growth in vivo. FANCI interactions with IMPDH2 and involvement in MEK/ERK/MMPs signaling were analyzed using co-immunoprecipitation assays, immunofluorescence microscopy, and Western blotting. Results: FANCI was identified as a hub gene for LUAD. FANCI expression was upregulated in LUAD tissues compared with normal lung tissues and was positively associated with lymphatic metastasis, distant metastasis, and poor outcome. FANCI was also an independent prognostic factor in LUAD patients. Knockdown of FANCI in LUAD cell lines decreased their proliferation, migration, invasion, and cell cycle progression in vitro, and decreased the growth of xenografts in mice. Direct binding of FANCI to IMPDH2 decreased IMPDH2 degradation, regulated activation of MEK/ERK/MMPs signaling. Overexpression of IMPDH2 reversed the inhibitory effects of FANCI knockdown. Conclusion: FANCI may act as an oncogene in LUAD by cooperating with IMPDH2 to promote cell proliferation via the MEK/ERK/MMPs pathway. These results identify FANCI as a potential prognostic biomarker and therapeutic target for LUAD.

References Powered by Scopus

IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways

138Citations
N/AReaders
Get full text

IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma

124Citations
N/AReaders
Get full text

p38α Activates Purine Metabolism to Initiate Hematopoietic Stem/Progenitor Cell Cycling in Response to Stress

83Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Focal point of fanconi anemia signaling

12Citations
N/AReaders
Get full text

Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma

9Citations
N/AReaders
Get full text

Aberrant R-loop–mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Zheng, P., & Li, L. (2020). FANCI cooperates with IMPDH2 to promote lung adenocarcinoma tumor growth via a MEK/ERK/ MMPS pathway. OncoTargets and Therapy, 13, 451–463. https://doi.org/10.2147/OTT.S230333

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

100%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 2

40%

Pharmacology, Toxicology and Pharmaceut... 2

40%

Medicine and Dentistry 1

20%

Save time finding and organizing research with Mendeley

Sign up for free